PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27593256-0	2016	Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma.	Yttrium-90	28-38	keratin 20	Homo sapiens	73-78	
15453924-1	2004	We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab standard therapy in 143 rituximab-naive patients with relapsed or refractory low-grade, follicular, or transformed CD20+ non-Hodgkin"s lymphoma (NHL).	Yttrium-90	84-94	keratin 20	Homo sapiens	245-249	
25596049-7	2014	Ibritumomab tiuxetan (Zevalin) is an anti-CD20 mouse monoclonal antibody labeled with Yttrium-90 (Y-90).	Yttrium-90	86-96	keratin 20	Homo sapiens	42-46	
16203814-1	2005	PURPOSE: Targeted radioimmunotherapy with yttrium-90 (90Y)-labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non-Hodgkin"s lymphoma.	Yttrium-90	42-52	keratin 20	Homo sapiens	200-204	
16091197-4	2005	Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well.	Yttrium-90	108-112	keratin 20	Homo sapiens	61-65	
23158095-3	2012	Radioimmunotherapy (RIT) with an anti-CD20 antibody linked to iodine-131 or to yttrium-90 has emerged as well-tolerated treatment after induction.	Yttrium-90	79-89	keratin 20	Homo sapiens	38-42	
17287964-5	2007	An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab.	Yttrium-90	88-97	keratin 20	Homo sapiens	32-36	
16540013-3	2006	90Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttrium-90 to the malignant B-cells.	Yttrium-90	91-101	keratin 20	Homo sapiens	52-56	
16304400-7	2005	Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well.	Yttrium-90	117-121	keratin 20	Homo sapiens	70-74	
15498146-1	2004	Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation.	Yttrium-90	39-49	keratin 20	Homo sapiens	190-194	
11258413-1	2001	The purpose of this study was to investigate whether marrow radiation absorbed dose estimates predict haematotoxicity following radioimmunotherapy with an yttrium-90 labelled anti-CD20 monoclonal antibody in non-Hodgkin"s B-cell lymphoma (NHL).	Yttrium-90	155-165	keratin 20	Homo sapiens	180-184	
12663713-1	2003	PURPOSE: Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of tumor response in patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL).	Yttrium-90	39-49	keratin 20	Homo sapiens	71-75	
11877757-11	2002	Yttrium-90 ((90)Y)--anti-CD20, which has little (90)Y excretion from the body, demonstrated the injected dose per body weight to be more predictive of marrow toxicity than indium-111 ((111)In) tracer dosimetry methods in heavily pretreated patients, and showed maximal safety with standard mCi/kg therapy dosing.	Yttrium-90	0-10	keratin 20	Homo sapiens	25-29	
11762415-0	2001	Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin"s lymphoma.	Yttrium-90	9-18	keratin 20	Homo sapiens	32-36	
11587375-1	2001	Clinical trials of an yttrium-90 (90Y)-conjugated monoclonal antibody to CD20 in patients with relapsed B cell non-Hodgkin lymphoma (NHL) are reviewed.	Yttrium-90	22-32	keratin 20	Homo sapiens	73-77	
15045033-1	2004	This article will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin"s lymphomas.	Yttrium-90	77-87	keratin 20	Homo sapiens	122-126	
12837157-0	2003	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin"s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.	Yttrium-90	119-129	keratin 20	Homo sapiens	33-37	
10561019-4	1999	Anti-CD20 antibodies radiolabeled with iodine 131 and yttrium 90 given at nonmyeloablative doses yield remissions in 75% to 80% of cases, including 35% to 40% complete remissions.	Yttrium-90	54-64	keratin 20	Homo sapiens	5-9	
9816191-0	1996	Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.	Yttrium-90	0-10	keratin 20	Homo sapiens	24-28